Keywords: roche, pegasys, fares, well, vs, peg-ifn, alfa-2b

Roche's Pegasys fares well vs peg-IFN alfa-2b

Article | 05 May 2008

Print This

Swiss drug major Roche says that new data from three studies indicate that chronic hepatitis C patients who received Pegasys ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in